Israelis such as UN Ambassador Ron Prosor in the video above are accepting participation in the ALS Challenge, taking their ice water baths and sending money to the very worthy charity. But their participation may not be the number one contribution to fighting this incurable disease; an Israeli treatment to ease symptoms and slow the progression of ALS and other incurable neuromuscular diseases is going into Phase 2 clinical trials in three major US medical centers.

BrainStorm Cell Therapeutics’, an Israeli company, has developed a technique for growing and enhancing stem cells harvested from patients’ own bone marrow. The enhanced cells secrete elevated levels of nerve-growth factors that protect existing motor neurons, promote motor neuron growth and reestablish nerve-muscle interaction.

According to website Israel 21C:

Two initial trials conducted at Jerusalem’s Hadassah University Medical Center led by stem-cell transplant pioneer Dr. Dimitrios Karussis, head of Hadassah’s Multiple Sclerosis Center, showed promising preliminary results in 24 patients.

take our poll - story continues below

Did SCOTUS make the right decision on medical mandates for large businesses?

• Did SCOTUS make the right decision on medical mandates for large businesses?  

• Are Democrat Lawmakers using Omicron to lock Americans down before Mid-Term elections?*
  • Yes!
  • No!
• Email*
• Name
  This field is for validation purposes and should be left unchanged.

Completing this poll grants you access to The Lid updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

“We are working on analysis of the data, but we can say there is some positive effect,” Karussis tells ISRAEL21c.

“In some of the parameters there was up to a 60 percent beneficial response after the treatment. We hope in the next three months we will have a paper ready to be published.”

Four ALS sufferers whose disease was too far advanced to join the study received the treatment as “compassionate cases.”

All four are alive as of this writing. Globally, some 90% of ALS patients die of respiratory failure within three to five years after the onset of symptoms, though a new study shows that in Israel, 20% of ALS patients survive past 10 years, possibly due to earlier diagnosis and treatment. As the disease progresses, patients lose the ability to stand or walk, and have difficulty breathing as the muscles of the respiratory system weaken.

All four had, at least for three to six months, a response of improvement in respiratory function or muscle power,” reports Karussis.

”The most impressive response was in the rabbi [octogenarian sage Rabbi Rafael Shmuelevitz], who had a very severe and unique combination of ALS and myasthenia gravis. He improved for about six months substantially, started walking and speaking, and then the effects faded and then we did a second injection and he had even more impressive improvement. This makes it highly unlikely to be a placebo effect, which is important to note.”

[Omri] Chotam [a former paratrooper in his 20s] also received two additional NurOwn injections through the compassionate use program, resulting in functional improvements and halting the progression of the disease for about 18 months now.

The data from the initial tests show a “beneficial change in the progression of the disease.” One of the issues to be tested in the U.S. trials will be the protocols and effects of multiple injections on the disease in the long term.

BrainStorm CEO Dr. Tony Fiorino tells ISRAEL21c that 48 patients will participate in the multicenter, double-blind, randomized trial beginning in Massachusetts General Hospital, the University of Massachusetts Memorial Hospital and the Mayo Clinic.

“Each of the three sites is headed by important thought leaders in the field of ALS,” he notes.

In this study approved by the US Food and Drug Administration (FDA), 36 of the patients will receive NurOwn enhanced stem cells from their own marrow, and 12 will receive a placebo. After the study is completed in early 2016, the results will be analyzed for safety and efficacy.

Should this trial be successful, the same treatment can be used to treat any disease involving the death of neurons, including multiple sclerosis and Parkinson’s.